Taylor Swift keeps Bruno Mars out of Billboard 200 top spot






LOS ANGELES (Reuters) – Country pop star Taylor Swift held her reign at the top of the Billboard 200 album chart on Wednesday, keeping retro-inspired R&B singer Bruno Mars‘ new album at bay.


Swift’s latest album, “Red,” released in October, held the No. 1 slot for a fifth non-consecutive week with sales of 208,000, according to figures from Nielsen SoundScan.






Mars’ second album, “Unorthodox Jukebox,” sold 192,000 copies in its opening week to take the No. 2 slot.


The album’s lead single, “Locked Out of Heaven,” stayed at the top spot on the Billboard Hot 100 chart for a second week, and is the singer’s fourth chart-topping single. It also tops the Digital Songs chart this week.


Hip hop artist The Game entered the chart at No. 6 with his fifth studio album, “Jesus Piece,” selling 86,000 copies.


Four festive albums sat in the top ten this week, with Michael Buble‘s “Christmas” at No. 3, Rod Stewart‘s “Merry Christmas Baby” at No. 5, Blake Shelton‘s “Cheers, It’s Christmas” at No. 8, and Lady Antebellum‘s “On This Winter’s Night” at No. 10.


(Reporting by Piya Sinha-Roy Editing by Jill Serjeant, Gary Hill)


Music News Headlines – Yahoo! News





Title Post: Taylor Swift keeps Bruno Mars out of Billboard 200 top spot
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

AP IMPACT: Steroids loom in major-college football






WASHINGTON (AP) — With steroids easy to buy, testing weak and punishments inconsistent, college football players are packing on significant weight — 30 pounds or more in a single year, sometimes — without drawing much attention from their schools or the NCAA in a sport that earns tens of billions of dollars for teams.


Rules vary so widely that, on any given game day, a team with a strict no-steroid policy can face a team whose players have repeatedly tested positive.






An investigation by The Associated Press — based on dozens of interviews with players, testers, dealers and experts and an analysis of weight records for more than 61,000 players — revealed that while those running the multibillion-dollar sport believe the problem is under control, that is hardly the case.


___


EDITOR’S NOTE — Whether for athletics or age, Americans from teenagers to baby boomers are trying to get an edge by illegally using anabolic steroids and human growth hormone, despite well-documented risks. This is the first of a two-part series.


___


The sport’s near-zero rate of positive steroids tests isn’t an accurate gauge among college athletes. Random tests provide weak deterrence and, by design, fail to catch every player using steroids. Colleges also are reluctant to spend money on expensive steroid testing when cheaper ones for drugs like marijuana allow them to say they’re doing everything they can to keep drugs out of football.


“It’s nothing like what’s going on in reality,” said Don Catlin, an anti-doping pioneer who spent years conducting the NCAA‘s laboratory tests at UCLA. He became so frustrated with the college system that it drove him in part to leave the testing industry to focus on anti-doping research.


Catlin said the collegiate system, in which players often are notified days before a test and many schools don’t even test for steroids, is designed to not catch dopers. That artificially reduces the numbers of positive tests and keeps schools safe from embarrassing drug scandals.


While other major sports have been beset by revelations of steroid use, college football has operated with barely a whiff of scandal. Between 1996 and 2010 — the era of Barry Bonds, Mark McGwire, Marion Jones and Lance Armstrong — the failure rate for NCAA steroid tests fell even closer to zero from an already low rate of less than 1 percent.


The AP’s investigation, drawing upon more than a decade of official rosters from all 120 Football Bowl Subdivision teams, found thousands of players quickly putting on significant weight, even more than their fellow players. The information compiled by the AP included players who appeared for multiple years on the same teams, making it the most comprehensive data available.


For decades, scientific studies have shown that anabolic steroid use leads to an increase in body weight. Weight gain alone doesn’t prove steroid use, but very rapid weight gain is one factor that would be deemed suspicious, said Kathy Turpin, senior director of sport drug testing for the National Center for Drug Free Sport, which conducts tests for the NCAA and more than 300 schools.


Yet the NCAA has never studied weight gain or considered it in regard to its steroid testing policies, said Mary Wilfert, the NCAA’s associate director of health and safety. She would not speculate on the cause of such rapid weight gain.


The NCAA attributes the decline in positive tests to its year-round drug testing program, combined with anti-drug education and testing conducted by schools.


“The effort has been increasing, and we believe it has driven down use,” Wilfert said.


Big gains, data show


The AP’s analysis found that, regardless of school, conference and won-loss record, many players gained weight at exceptional rates compared with their fellow athletes and while accounting for their heights. The documented weight gains could not be explained by the amount of money schools spent on weight rooms, trainers and other football expenses.


Adding more than 20 or 25 pounds of lean muscle in a year is nearly impossible through diet and exercise alone, said Dan Benardot, director of the Laboratory for Elite Athlete Performance at Georgia State University.


The AP’s analysis corrected for the fact that players in different positions have different body types, so speedy wide receivers weren’t compared to bulkier offensive tackles. It could not assess each player’s physical makeup, such as how much weight gain was muscle versus fat, one indicator of steroid use. In the most extreme case in the AP analysis, the probability that a player put on so much weight compared with other players was so rare that the odds statistically were roughly the same as an NFL quarterback throwing 12 passing touchdowns or an NFL running back rushing for 600 yards in one game.


In nearly all the rarest cases of weight gain in the AP study, players were offensive or defensive linemen, hulking giants who tower above 6-foot-3 and weigh 300 pounds or more. Four of those players interviewed by the AP said that they never used steroids and gained weight through dramatic increases in eating, up to six meals a day. Two said they were aware of other players using steroids.


“I just ate. I ate 5-6 times a day,” said Clint Oldenburg, who played for Colorado State starting in 2002 and for five years in the NFL. Oldenburg’s weight increased over four years from 212 to 290, including a one-year gain of 53 pounds, which he attributed to diet and two hours of weight lifting daily. “It wasn’t as difficult as you think. I just ate anything.”


Oldenburg told the AP he was surprised at the scope of steroid use in college football, even in Colorado State’s locker room. “College performance enhancers were more prevalent than I thought,” he said. “There were a lot of guys even on my team that were using.” He declined to identify any of them.


The AP found more than 4,700 players — or about 7 percent of all players — who gained more than 20 pounds overall in a single year. It was common for the athletes to gain 10, 15 and up to 20 pounds in their first year under a rigorous regimen of weightlifting and diet. Others gained 25, 35 and 40 pounds in a season. In roughly 100 cases, players packed on as much 80 pounds in a single year.


In at least 11 instances, players that AP identified as packing on significant weight in college went on to fail NFL drug tests. But pro football’s confidentiality rules make it impossible to know for certain which drugs were used and how many others failed tests that never became public.


What is bubbling under the surface in college football, which helps elite athletes gain unusual amounts of weight? Without access to detailed information about each player’s body composition, drug testing and workout regimen, which schools do not release, it’s impossible to say with certainty what’s behind the trend. But Catlin has little doubt: It is steroids.


“It’s not brain surgery to figure out what’s going on,” he said. “To me, it’s very clear.”


Football’s most infamous steroid user was Lyle Alzado, who became a star NFL defensive end in the 1970s and ’80s before he admitted to juicing his entire career. He started in college, where the 190-pound freshman gained 40 pounds in one year. It was a 21 percent jump in body mass, a tremendous gain that far exceeded what researchers have seen in controlled, short-term studies of steroid use by athletes. Alzado died of brain cancer in 1992.


The AP found more than 130 big-time college football players who showed comparable one-year gains in the past decade. Students posted such extraordinary weight gains across the country, in every conference, in nearly every school. Many of them eclipsed Alzado and gained 25, 35, even 40 percent of their body mass.


Even though testers consider rapid weight gain suspicious, in practice it doesn’t result in testing. Ben Lamaak, who arrived at Iowa State in 2006, said he weighed 225 pounds in high school and 262 pounds in the summer of his freshman year on the Cyclones football team. A year later, official rosters showed the former basketball player from Cedar Rapids weighed 306, a gain of 81 pounds since high school. He graduated as a 320-pound offensive lineman and said he did it all naturally.


“I was just a young kid at that time, and I was still growing into my body,” he said. “It really wasn’t that hard for me to gain the weight. I had fun doing it. I love to eat. It wasn’t a problem.”


In addition to random drug testing, Iowa State is one of many schools that have “reasonable suspicion” testing. That means players can be tested when their behavior or physical symptoms suggest drug use.


Despite gaining 81 pounds in a year, Lamaak said he was never singled out for testing.


The associate athletics director for athletic training at Iowa State, Mark Coberley, said coaches and trainers use body composition, strength data and other factors to spot suspected cheaters. Lamaak, he said, was not suspicious because he gained a lot of “non-lean” weight.


“There are a lot of things that go into trying to identify whether guys are using performance-enhancing drugs,” Coberley said. “If anybody had the answer, they’d be spotting people that do it. We keep our radar up and watch for things that are suspicious and try to protect the kids from making stupid decisions.”


There’s no evidence that Lamaak’s weight gain was anything but natural. Gaining fat is much easier than gaining muscle. But colleges don’t routinely release information on how much of the weight their players gain is muscle, as opposed to fat. Without knowing more, said Benardot, the expert at Georgia State, it’s impossible to say whether large athletes were putting on suspicious amounts of muscle or simply obese, which is defined as a body mass index greater than 30.


Looking solely at the most significant weight gainers also ignores players like Bryan Maneafaiga.


In the summer of 2004, Maneafaiga was an undersized 180-pound running back trying to make the University of Hawaii football team. Twice — once in pre-season and once in the fall — he failed school drug tests, showing up positive for marijuana use. What surprised him was that the same tests turned up negative for steroids.


He’d started injecting stanozolol, a steroid, in the summer to help bulk up to a roster weight of 200 pounds. Once on the team, where he saw only limited playing time, he’d occasionally inject the milky liquid into his buttocks the day before games.


“Food and good training will only get you so far,” he told the AP recently.


Maneafaiga’s coach, June Jones, meanwhile, said none of his players had tested positive for doping since he took over the team in 1999. He also said publicly that steroids had been eliminated in college football: “I would say 100 percent,” he told The Honolulu Advertiser in 2006.


Jones said it was news to him that one of his players had used steroids. Jones, who now coaches at Southern Methodist University, said many of his former players put on bulk working hard in the weight room. For instance, adding 70 pounds over a three- to four-year period isn’t unusual, he said.


Jones said a big jump in muscle year-over-year — say 40 pounds — would be a “red light that something is not right.”


Jones, a former NFL head coach, said he is unaware of any steroid use at SMU and believes the NCAA is doing a good job testing players. “I just think because the way the NCAA regulates it now that it’s very hard to get around those tests,” he said.


The cost of testing


While the use of drugs in professional sports is a question of fairness, use among college athletes is also important as a public policy issue. That’s because most top-tier football teams are from public schools that benefit from millions of dollars each year in taxpayer subsidies. Their athletes are essentially wards of the state. Coaches and trainers — the ones who tell players how to behave, how to exercise and what to eat — are government employees.


Then there are the health risks, which include heart and liver problems and cancer.


On paper, college football has a strong drug policy. The NCAA conducts random, unannounced drug testing and the penalties for failure are severe. Players lose an entire year of eligibility after a first positive test. A second offense means permanent ineligibility from sports.


In practice, though, the NCAA’s roughly 11,000 annual tests amount to just a fraction of all athletes in Division I and II schools. Exactly how many tests are conducted each year on football players is unclear because the NCAA hasn’t published its data for two years. And when it did, it periodically changed the formats, making it impossible to compare one year of football to the next.


Even when players are tested by the NCAA, people involved in the process say it’s easy enough to anticipate the test and develop a doping routine that results in a clean test by the time it occurs. NCAA rules say players can be notified up to two days in advance of a test, which Catlin says is plenty of time to beat a test if players have designed the right doping regimen. By comparison, Olympic athletes are given no notice.


“Everybody knows when testing is coming. They all know. And they know how to beat the test,” Catlin said, adding, “Only the really dumb ones are getting caught.”


Players are far more likely to be tested for drugs by their schools than by the NCAA. But while many schools have policies that give them the right to test for steroids, they often opt not to. Schools are much more focused on street drugs like cocaine and marijuana. Depending on how many tests a school orders, each steroid test can cost $ 100 to $ 200, while a simple test for street drugs might cost as little as $ 25.


When schools call and ask about drug testing, the first question is usually, “How much will it cost,” Turpin said.


Most schools that use Drug Free Sport do not test for anabolic steroids, Turpin said. Some are worried about the cost. Others don’t think they have a problem. And others believe that since the NCAA tests for steroids their money is best spent testing for street drugs, she said.


Wilfert, the NCAA official, said the possibility of steroid testing is still a deterrent, even at schools where it isn’t conducted.


“Even though perhaps those institutional programs are not including steroids in all their tests, they could, and they do from time to time,” she said. “So, it is a kind of deterrence.”


For Catlin, one of the most frustrating things about running the UCLA testing lab was getting urine samples from schools around the country and only being asked to test for cocaine, marijuana and the like.


“Schools are very good at saying, ‘Man, we’re really strong on drug testing,’” he said. “And that’s all they really want to be able to say and to do and to promote.”


That helps explain how two school drug tests could miss Maneafaiga’s steroid use. It’s also possible that the random test came at an ideal time in Maneafaiga’s steroid cycle.


Enforcement varies


The top steroid investigator at the U.S. Drug Enforcement Administration, Joe Rannazzisi, said he doesn’t understand why schools don’t invest in the same kind of testing, with the same penalties, as the NFL. The NFL has a thorough testing program for most drugs, though the league has yet to resolve a long-simmering feud with its players union about how to test for human growth hormone.


“Is it expensive? Of course, but college football makes a lot of money,” he said. “Invest in the integrity of your program.”


For a school to test all 85 scholarship football players for steroids twice a season would cost up to $ 34,000, Catlin said, plus the cost of collecting and handling the urine samples. That’s about 0.2 percent of the average big-time school football budget of about $ 14 million. Testing all athletes in all sports would make the school’s costs higher.


When schools ask Drug Free Sport for advice on their drug policies, Turpin said she recommends an immediate suspension after the first positive drug test. Otherwise, she said, “student athletes will roll the dice.”


But drug use is a bigger deal at some schools than others.


At Notre Dame and Alabama, the teams that will soon compete for the national championship, players don’t automatically miss games for testing positive for steroids. At Alabama, coaches have wide discretion. Notre Dame’s student-athlete handbook says a player who fails a test can return to the field once the steroids are out of his system.


“If you’re a strength-and-conditioning coach, if you see your kids making gains that seem a little out of line, are you going to say, ‘I’m going to investigate further? I want to catch someone?’” said Anthony Roberts, an author of a book on steroids who says he has helped college football players design steroid regimens to beat drug tests.


There are schools with tough policies. The University of North Carolina kicks players off the team after a single positive test for steroids. Auburn’s student-athlete handbook calls for a half-season suspension for any athlete caught using performance-enhancing drugs.


Wilfert said it’s not up to the NCAA to determine whether that’s fair.


“Obviously if it was our testing program, we believe that everybody should be under the same protocol and the same sanction,” she said.


Fans typically have no idea that such discrepancies exist and players are left to suspect who might be cheating.


“You see a lot of guys and you know they’re possibly on something because they just don’t gain weight but get stronger real fast,” said Orrin Thompson, a former defensive lineman at Duke. “You know they could be doing something but you really don’t know for sure.”


Thompson gained 85 pounds between 2001 and 2004, according to Duke rosters and Thompson himself. He said he did not use steroids and was subjected to several tests while at Duke, a school where a single positive steroid test results in a yearlong suspension.


Meanwhile at UCLA, home of the laboratory that for years set the standard for cutting-edge steroid testing, athletes can fail three drug tests before being suspended. At Bowling Green, testing is voluntary.


At the University of Maryland, students must get counseling after testing positive, but school officials are prohibited from disciplining first-time steroid users. Athletic department spokesman Matt Taylor denied that was the case and sent the AP a copy of the policy. But the policy Taylor sent included this provision: “The athletic department/coaching staff may not discipline a student-athlete for a first drug offense.”


By comparison, in Kentucky and Maryland, racehorses face tougher testing and sanctions than football players at Louisville or the University of Maryland.


“If you’re trying to keep a level playing field, that seems nonsensical,” said Rannazzisi at the DEA. He said he was surprised to learn that what gets a free pass at one school gets players immediately suspended at another. “What message does that send? It’s OK to cheat once or twice?”


Only about half the student athletes in a 2009 NCAA survey said they believed school testing deterred drug use.


As an association of colleges and universities, the NCAA could not unilaterally force schools to institute uniform testing policies and sanctions, Wilfert said.


“We can’t tell them what to do, but if went through a membership process where they determined that this is what should be done, then it could happen,” she said.


‘Everybody around me was doing it’


Steroids are a controlled substance under federal law, but players who use them need not worry too much about prosecution. The DEA focuses on criminal operations, not individual users. When players are caught with steroids, it’s often as part of a traffic stop or a local police investigation.


Jared Foster, 24, a quarterback recruited to play at the University of Mississippi, was kicked off the team in 2008 after local authorities arrested him for giving a man nandrolone, an anabolic steroid, according to court documents. Foster pleaded guilty and served jail time.


He told the AP that he doped in high school to impress college recruiters. He said he put on enough lean muscle to go from 185 pounds to 210 in about two months.


“Everybody around me was doing it,” he said.


Steroids are not hard to find. A simple Internet search turns up countless online sources for performance-enhancing drugs, mostly from overseas companies.


College athletes freely post messages on steroid websites, seeking advice to beat tests and design the right schedule of administering steroids.


And steroids are still a mainstay in private, local gyms. Before the DEA shut down Alabama-based Applied Pharmacy Services as a major nationwide steroid supplier, sales records obtained by the AP show steroid shipments to bodybuilders, trainers and gym owners around the country.


Because users are rarely prosecuted, the demand is left in place after the distributor is gone.


When Joshua Hodnik was making and wholesaling illegal steroids, he had found a good retail salesman in a college quarterback named Vinnie Miroth. Miroth was playing at Saginaw Valley State, a Division II school in central Michigan, and was buying enough steroids for 25 people each month, Hodnik said.


“That’s why I hired him,” Hodnik said. “He bought large amounts and knew how to move it.”


Miroth, who pleaded no contest in 2007 and admitted selling steroids, helped authorities build their case against Hodnik, according to court records. Now playing football in France, Miroth declined repeated AP requests for an interview.


Hodnik was released from prison this year and says he is out of the steroid business for good. He said there’s no doubt that steroid use is widespread in college football.


“These guys don’t start using performance-enhancing drugs when they hit the professional level,” the Oklahoma City man said. “Obviously it starts well before that. And you can go back to some of the professional players who tested positive and compare their numbers to college and there is virtually no change.”


Maneafaiga, the former Hawaii running back, said his steroids came from Mexico. A friend in California, who was a coach at a junior college, sent them through the mail. But Maneafaiga believes the consequences were nagging injuries. He found religion, quit the drugs and became the team’s chaplain.


“God gave you everything you need,” he said. “It gets in your mind. It will make you grow unnaturally. Eventually, you’ll break down. It happened to me every time.”


At the DEA, Rannazzisi said he has met with and conducted training for investigators and top officials in every professional sport. He’s talked to Major League Baseball about the patterns his agents are seeing. He’s discussed warning signs with the NFL.


He said he’s offered similar training to the NCAA but never heard back. Wilfert said the NCAA staff has discussed it and hasn’t decided what to do.


“We have very little communication with the NCAA or individual schools,” Rannazzisi said. “They’ve got my card. What they’ve done with it? I don’t know.”


___


Associated Press writers Ryan Foley in Cedar Rapids, Iowa; David Brandt in Jackson, Miss.; David Skretta in Lawrence, Kan.; Don Thompson in Sacramento, Calif.;and Alexa Olesen in Shanghai, China; and researchers Susan James in New York and Monika Mathur in Washington contributed to this report.


___


Contact the Washington investigative team at DCinvestigations (at) ap.org.


Whether for athletics or age, Americans from teenagers to baby boomers are trying to get an edge by illegally using anabolic steroids and human growth hormone, despite well-documented risks. This is the first of a two-part series.


Health News Headlines – Yahoo! News





Title Post: AP IMPACT: Steroids loom in major-college football
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

State Department security chief leaves post over Benghazi






WASHINGTON (Reuters) – The U.S. State Department said on Wednesday its security chief had resigned from his post and three other officials had been relieved of their duties following a scathing official inquiry into the September 11 attack on the U.S. mission in Benghazi.


Eric Boswell has resigned effective immediately as assistant secretary of state for diplomatic security, State Department spokeswoman Victoria Nuland said in a terse statement. A second official, speaking on condition of anonymity, said Boswell had not left the department entirely and remained a career official.






Nuland said that Boswell, and the three other officials, had all been put on administrative leave “pending further action.”


An official panel that investigated the incident concluded that the Benghazi mission was completely unprepared to deal with the attack, which killed U.S. Ambassador Christopher Stevens and three other Americans.


The unclassified version of the report, which was released on Tuesday, cited “leadership and management” deficiencies, poor coordination among officials and “real confusion” in Washington and in the field over who had the authority to make decisions on policy and security concerns.


“The ARB identified the performance of four officials, three in the Bureau of the Diplomatic Security and one in the Bureau of (Near Eastern) Affairs,” Nuland said in her statement, referring to the panel known as an Accountability Review Board.


Secretary of State Hillary Clinton accepted Boswell’s decision to resign effective immediately, the spokeswoman said.


Earlier, a U.S. official who spoke on condition of anonymity said Boswell, one of his deputies, Charlene Lamb, and a third unnamed official has been asked to resign. The Associated Press first reported that three officials had resigned.


PANEL STOPS SHORT OF BLAMING CLINTON


The Benghazi incident appeared likely to tarnish Clinton’s four-year tenure as secretary of state but the report did not fault her specifically and the officials who led the review stopped short of blaming her.


“We did conclude that certain State Department bureau-level senior officials in critical positions of authority and responsibility in Washington demonstrated a lack of leadership and management ability appropriate for senior ranks,” retired Admiral Michael Mullen, one of the leaders of the inquiry, told reporters on Wednesday.


The panel’s chair, retired Ambassador Thomas Pickering, said it had determined that responsibility for security shortcomings in Benghazi belonged at levels lower than Clinton’s office.


“We fixed (responsibility) at the assistant secretary level, which is, in our view, the appropriate place to look for where the decision-making in fact takes place, where – if you like – the rubber hits the road,” Pickering said after closed-door meetings with congressional committees.


The panel’s report and the comments by its two lead authors suggested that Clinton, who accepted responsibility for the incident in a television interview about a month after the Benghazi attack, would not be held personally culpable.


Pickering and Mullen spoke to the media after briefing members of the House of Representatives Foreign Affairs Committee and Senate Foreign Relations Committee behind closed doors on classified elements of their report.


Clinton had been expected to appear at an open hearing on Benghazi on Thursday, but is recuperating after suffering a concussion, dehydration and a stomach bug last week. She will instead be represented by her two top deputies.


Clinton, who intends to step down in January, said in a letter accompanying the review that she would adopt all of its recommendations, which include stepping up security staffing and requesting more money to fortify U.S. facilities.


The National Defense Authorization Act for 2013, which is expected to go to Congress for final approval this week, includes a measure directing the Pentagon to increase the Marine Corps presence at diplomatic facilities by up to 1,000 Marines.


Some Capitol Hill Republicans who had criticized the Obama administration’s handling of the Benghazi attacks said they were impressed by the report.


“It was very thorough,” said Senator Johnny Isakson. Senator John Barrasso said: “It was very, very critical of major failures at the State Department at very high levels.” Both spoke after the closed-door briefing.


Others, however, took a harsher line and called for Clinton to testify as soon as she is able.


“The report makes clear the massive failure of the State Department at all levels, including senior leadership, to take action to protect our government employees abroad,” Representative Mike Rogers, the Republican chairman of the House Intelligence Committee, said in a statement.


Senator Bob Corker, who will be the top Republican on the Senate Foreign Relations Committee when the new Congress is seated early next year, said Clinton should testify about Benghazi before her replacement is confirmed by the Senate.


Republicans have focused much of their firepower on U.S. Ambassador to the United Nations Susan Rice, who appeared on TV talk shows after the attack and suggested it was the result of a spontaneous protest rather than a premeditated attack.


The report concluded that there was no such protest.


Rice, widely seen as President Barack Obama’s top pick to succeed Clinton, withdrew her name from consideration last week.


(Additional reporting by Tabassum Zakaria and Susan Cornwell; Editing by Christopher Wilson)


World News Headlines – Yahoo! News





Title Post: State Department security chief leaves post over Benghazi
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

IntercontinentalExchange buys NYSE Euronext for $8 billion






NEW YORK/LONDON (Reuters) – IntercontinentalExchange struck an $ 8.2 billion deal to buy NYSE Euronext, a combination that will propel the commodities market powerhouse into European financial futures but threaten to further reduce the clout of the New York Stock Exchange.


The deal will create a new player in global derivatives trading and clearing that would take on CME Group Inc. While the New York Stock Exchange has stood for 200 years as an iconic symbol of U.S. capitalism, it is almost an afterthought in this deal.






Atlanta-based ICE said it will try to spin off the Euronext European stock market businesses in a public offering, generating speculation it may eventually shutter the NYSE‘s trading floor, as well. Profits from stock trading have been significantly eroded by new technology and the rise of private venues run by Wall Street banks and brokers.


Analysts said the deal will give ICE a strategic boost with control of Liffe, Europe’s second-largest derivatives market, helping it compete against U.S.-based CME Group, owner of the Chicago Board of Trade. Derivatives trading remains quite profitable for the exchanges and new rules coming into play next year will dramatically expand the demand for clearing over-the-counter contracts.


Regulatory concerns sank two deals to buy NYSE Euronext last year, including a joint bid by ICE and Nasdaq OMX Group and a separate bid from German exchange Deutsche Bourse. But ICE alone has far less overlapping business and should face easy approvals, antitrust attorneys said.


The deal values each NYSE Euronext share at $ 33.12, a 28 percent premium to the stock’s closing price on Wednesday. Shareholders will have the option of accepting $ 33.12 in cash per NYSE Euronext share or 0.2581 ICE share or a mix of $ 11.27 in cash and 0.1703 ICE share, subject to a maximum cash consideration of $ 2.7 billion..


NYSE Euronext stock rose 33 percent, to $ 31.88, after the deal was announced. ICE’s shares fell as much as 4 percent before clawing back some of the losses to trade down 0.6 percent, at $ 127.60, at 01:10 p.m. ET.


ICE said it would pay an annual dividend of $ 300 million once the deal closes.


NYSE Chief Executive Duncan Niederauer called the deal a “no brainer” on a call with analysts on Thursday. Further consolidation of exchanges was “inevitable” and ICE was a “great partner,” he said, so continuing on alone did not make sense.


“We can sit here and keep slugging away and keep working hard, but the bottom line is we had not delivered, in my mind, sufficient returns to shareholders,” Niederauer said.


Before the latest ICE offer emerged, NYSE Euronext‘s shares had fallen by nearly a third since ICE and Nasdaq launched their thwarted joint bid.


The newest offer first took shape in October when ICE Chairman and Chief Executive Jeff Sprecher, a consummate deal maker, called Niederauer to consider reviving their talks without the Nasdaq involved, said one person familiar with the situation who was not authorized to speak to the press.


ICE started out as an online marketplace for energy trading before Sprecher initiated a string of acquisitions from the London-based International Petroleum Exchange in 2001, to the New York Board of Trade and, most recently, a handful of smaller deals, including a climate exchange and a stake in a Brazilian clearing house.


A tie-up with Liffe would give Sprecher a boost to trade in to interest rates, one of the world’s biggest asset classes and a particular specialty of CME. Liffe and CME have a long-time rivalry in trading of short-term interest-rate contracts, with each launching – to little effect – look-alike versions of the other’s contracts. The CME declined to comment on the proposed deal.


“ICE is after Liffe, that is the crown jewel of NYSE Euronext,” said Peter Lenardos, analyst at RBC Capital Markets. NYSE bought Euronext, including Liffe, for 8 billion euros in 2007. “Strategically it makes sense for ICE to enter the European derivatives space in a meaningful way.”


ICE’s current main operations are in energy futures trading and, it has steered clear of stocks and stock-options trading, key businesses for NYSE Euronext. So there is not much business overlap between the two groups compared with last year’s proposed takeovers.


“This deal is probably not going to generate a lot of concern from an antitrust perspective,” said Warren Rosborough, a veteran of the U.S. Justice Department’s antitrust division who is now with the law firm McDermott Will & Emery.


A small amount of competing derivatives business could be addressed with straightforward divestitures, he said. “It’s an open question about whether it will generate questions,” he said. “If there is a fix, it will be relatively easy fix.”


Sprecher, who will be chairman and CEO of the combined company, said the deal had been “well received” by regulators after he and Niederauer completed a “whirlwind tour” in the United States and Europe ahead of Thursday’s announcement. Officials at the European Commission and the U.S. Securities and Exchange Commission declined to comment.


Last year, the Justice Department blocked a $ 11 billion joint hostile bid by ICE and Nasdaq OMX on concerns the tie-up would dominate U.S. stock listings. A rival $ 9.3 billion bid by Deutsche Boerse fell afoul of European regulators.


A combined ICE-NYSE Euronext would leap-frog Deutsche Boerse to become the world’s third-largest exchange group with a combined market value of $ 15.2 billion. CME Group has a market value of $ 17.5 billion, Thomson Reuters data shows.


Hong Kong Exchanges and Clearing is the world’s largest exchange group with a market cap of $ 19.5 billion.


ICE said it expected to achieve $ 450 million in cost savings from the takeover. In the first year after the deal closes, additional earnings of 15 percent are expected.


Long-time Wall Street traders saw the potential takeover of the venerable stock exchange by a 12-year-old derivatives upstart as weighted with symbolism.


“It’s the end of an era,” said a director on the board of a rival exchange who did not have clearance to speak to the press and asked not to be named. “I think ultimately the floor will be closed, because Jeff (Sprecher) has shut every floor he’s ever had,” the person said.


The exchange was prepared to shut down the floor temporarily during superstorm Sandy and trade completely electronically, Wall Street executives said.


But one former New York Stock Exchange executive was doubtful that ICE would completely shut down the NYSE floor. “It has too strong a marketing brand associated with it to close it,” said the executive, who declined to be identified because he is not permitted to speak to the press.


Morgan Stanley was the lead financial adviser to ICE, with assistance from BMO Capital Markets Corp, Broadhaven Capital Partners, JPMorgan Chase & Co, Lazard Group LLC, Societe Generale Corporate & Investment Banking, and Wells Fargo Securities LLC. ICE legal advisers are Sullivan & Cromwell LLP and Shearman & Sterling LLP.


The principal financial advisers to NYSE Euronext are Perella Weinberg Partners and BNP Paribas. Further financial advice to NYSE Euronext is being provided by Blackstone Advisory Partners, Citigroup, Goldman Sachs & Co. and Moelis & Co. Legal advisers to NYSE Euronext are Wachtell, Lipton, Rosen & Katz, Slaughter & May, and Stibbe NV.


(Additional reporting by Luke Jeffs and David Brough in London, Jessica Toonkel, Diane Bartz and Karen Brettell in New York, Sarah N. Lynch in Washington and Ann Saphir in Chicago; writing by Carmel Crimmins and Aaron Pressman; editing by Philippa Fletcher)


Business News Headlines – Yahoo! News





Title Post: IntercontinentalExchange buys NYSE Euronext for $8 billion
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Madonna leads Billboard’s top-grossing tours






LOS ANGELES (Reuters) – While this year’s pop charts have been dominated by young singers, it is veteran music stars, led by Madonna, who are commanding big money in tour ticket sales, according to a new Billboard list released on Tuesday.


Madonna, 54, topped Billboard‘s list of highest-grossing live tours, earning an estimated $ 228.4 million in ticket sales from her sold-out ninth worldwide tour in support of her 12th studio album “MDNA.” The singer will wrap her tour in South America this weekend, after performing more than 80 shows across the world starting in Israel in May.






Madonna came ahead of pop star Lady Gaga, who landed at No. 6, with ticket sales of $ 124.9 million from her worldwide “Born This Way Ball” tour. Gaga, 26, is currently midway through her tour, which kicked off in South Korea in April, and will wrap in Oklahoma in March 2013.


Music publication Billboard compiled its list through estimated gross ticket sales figures from Billboard box scores, which tracks concert tours, ticket prices and sales.


The top five highest-grossing tour acts of 2012 included Bruce Springsteen, 63, and the E Street band at No. 2 with $ 199 million from 72 shows and Pink Floyd’s Roger Waters, 69, at No. 3 with $ 186 million.


Cirque Du Soleil‘s homage to late singer Michael Jackson in “The Immortal World Tour” ranked No. 4 with $ 147.3 million over 183 shows, and British rock band Coldplay was fifth with $ 147.2 million over 67 shows.


The only other young stars in the list of 25 top-grossing tours was Canadian pop star Justin Bieber, 18, at No. 20 with $ 30 million from 29 shows as part of his ongoing “Believe” tour, and country-pop darling Taylor Swift, 23, who raked in $ 26 million from 21 shows from her “Speak Now World Tour.”


Last year, Swift ranked No. 5 on Billboard‘s list with an estimated $ 97 million in ticket sales from her “Speak Now World Tour,” while Bieber came in at No. 15 with $ 44 million.


Swift will embark on her third worldwide concert tour in support of her studio album “Red” in March 2013.


(Reporting By Piya Sinha-Roy; Editing by Patricia Reaney and Eric Walsh)


Music News Headlines – Yahoo! News





Title Post: Madonna leads Billboard’s top-grossing tours
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Drugs group Lundbeck’s shares hit by profit warning






COPENHAGEN (Reuters) – Shares in Danish drugs firm Lundbeck fell to their lowest level in over 12 years on Wednesday after it cut its profits forecast for the next two years as European sales slow and spending on new products rise to combat generic competition.


The company has already warned that earnings would stall until 2015 due to cheap generic competition for its existing drugs, meaning new products will be vital for future earnings.






But Chief Executive Ulf Wiinberg said on Wednesday that the negative impact on revenue from healthcare reforms in Europe had also been bigger than expected in the last two years and that slowing European sales and generic competition were hurting.


As a result the company said operating profits would fall further than previously forecast in 2014 as it increases investments in its late-stage drugs development pipeline and product launches.


Lundbeck is working to find new drugs to replace lost revenue from products coming off patent protection such as its antidepressant Cipralex, which is sold as Lexapro in the United States and Japan, and Alzheimer’s drug Ebixa.


Wiinberg said 2014 would be the company’s peak investment year for the new products pipeline, offering it a solid foundation for growth starting in 2015.


“You only get one chance to launch a product and we have to do it well,” Wiinberg said at a briefing for investors.


He was commenting after the company warned in a statement that it now expects revenue in 2014 of about 14 billion Danish crowns ($ 2.5 billion) and an operating profit of between just 0.5 billion and 1 billion crowns.


Analysts have on average been forecasting a profit of over 2.5 billion crowns for 2014 on turnover of over 14.7 billion crowns, according to Thomson Reuters I/B/E/S Estimates.


Two years ago Lundbeck predicted its annual revenues over the period 2012-2014 would exceed 14 billion crowns a year while earnings before interest and tax (EBIT) would exceed 2 billion crowns a year.


Next years’ revenue is now forecast to be in the range of 14.1 billion and 14.7 billion crowns to produce an operating profit of 1.6 billion to 2.1 billion crowns, with no change to the company’s forecast for 2012.


Analysts’ forecasts for this year are for operating profit to drop 41 percent to 1.99 billion crowns on revenue down 8 percent at 14.7 billion crowns, while for 2013 they predict a profit of 2.26 billion crowns on revenue of 14.5 billion crowns.


Lundbeck’s shares were trading down 17 percent at 79.90 crowns at 12.44 p.m. British time, dropping below 80 crowns for the first time since April 2000.


“In the short term, earnings are under pressure,” Sydbank analyst Soren Hansen said.


Lundbeck said that it expects a dividend payout ratio of about 35 percent of net profits in the 2012-14 period. Last year it paid 3.49 crowns on basic earnings per share of 11.64 crowns, a payout ratio of 30 percent.


Analysts have been predicting a 27-30 percent cut this year to 2.53-2.28 crowns, according to Thomson Reuters StarMine data.


But a number of analysts doubt that revenue from new products will be enough to secure revenue growth in 2015, compensating for lost revenue from Cipralex, Lexapro and Ebixa which together accounted for about 70 percent of group revenue in 2011.


Lundbeck is working on new products such as antidepressant Brintellix in Europe and the United States for launch at the end of next year or start of 2014, as well as alcohol dependency treatment Selincro in Europe in mid 2013.


“It is difficult to see revenue from the smaller products compensating for the large products,” said Hansen.


“They have a lot of new products in the portfolio and a lot of products in the pipeline, but revenue growth in 2015 is not very likely,” he said. ($ 1=5.6458 Danish crowns)


(Editing by Greg Mahlich)


Medications/Drugs News Headlines – Yahoo! News





Title Post: Drugs group Lundbeck’s shares hit by profit warning
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Bank chief house costs to be paid







Mark Carney, the next head of the Bank of England, will be paid £250,000 in housing costs in addition to his salary and pension costs.






He will receive the money on top of his annual £480,000 salary and a yearly pension allowance of £144,000.


The housing allowance will be taxed at the new top rate of tax of 45%, which will be in place by the time he takes up his post next July,


Mr Carney is currently the head of the Bank of Canada.


A housing allowance was agreed as part of the package to tempt Mr Carney, who lives with his wife and four children, from his current post in Canada, but has only just been signed off by the non-executive directors of the Bank of England.


The allowance is designed to help him maintain a similar lifestyle to his current one in Ottawa, where he has a spacious family house near the Bank of Canada’s headquarters.


Continue reading the main story

What may stir controversy is that Mr Carney’s package protects him from the kind of gyrations in the economy that it will be his role to temper”



End Quote



Mr Carney’s salary itself is well above the £305,000 paid to the current governor of the Bank of England, Sir Mervyn King.


The Bank says this reflects in part the increased role the next governor will be faced with, as the Bank is taking over most of the UK’s bank regulation from the Financial Services Authority next year.


The Chancellor, George Osborne, spent months trying to court Mr Carney to take the post as Bank chief.


Mr Carney had gone on record as saying he was not interested in the post, but was persuaded to change his mind by Mr Osborne.


Part of the deal included allowing Mr Carney to serve just five years as Bank governor, rather than the eight-year term normally served in that position.


BBC News – Business





Title Post: Bank chief house costs to be paid
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

EU’s Almunia sets deadline for Google antitrust plan






BRUSSELS (Reuters) – The European Union set Google an ultimatum on Tuesday, giving it a month to come up with detailed proposals to resolve a two-year investigation into complaints that it used its power to block rivals, including Microsoft.


The EU’s antitrust chief, Joaquin Almunia, delivered the deadline in a meeting with Google Executive Chairman Eric Schmidt in Brussels.






If it fails to address the complaints, the world’s most popular search engine could face a lengthy battle with what is arguably the world’s most powerful antitrust authority. If found guilty, it could mean a fine of up to 10 percent of its revenue, or $ 4 billion.


“Since our preliminary talks with Google started in July, we have substantially reduced our differences regarding possible ways to address each of the four competition concerns expressed by the Commission,” Almunia said in a statement.


“On the basis of the progress made, I now expect Google to come forward with a detailed commitment text in January 2013.”


Almunia said he would seek feedback from rivals and users once he has received Google’s proposal.


Google said it continues to work co-operatively with the Commission.


The European Commission has been examining informal settlement proposals from Google since July but has not sought feedback from the complainants, suggesting it is not convinced by what Google has put on the table so far.


The EU watchdog’s two-year investigation has centered on complaints that Google unfairly favored its services over its rivals in search results, and that it may have copied material from travel and restaurant websites without permission.


The Commission is also looking into whether Google restricted advertisers from transferring their data to rivals.


The Commission’s decision to press Google to offer more far-reaching concessions comes in sharp contrast to the case U.S. regulators have against the company.


Sources told Reuters the U.S. Federal Trade Commission could drop their investigation into Google without requiring any major change in how the company does business.


(Reporting by Foo Yun Chee; Editing by Robin Emmott, Louise Heavens and Nick Zieminski)


Tech News Headlines – Yahoo! News





Title Post: EU’s Almunia sets deadline for Google antitrust plan
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Ben Stiller’s Red Hour sells two more comedies to ABC Studios






LOS ANGELES (TheWrap.com) – Ben Stiller‘s Red Hour Television is continuing to pump out comedies for ABC Studios.


Following the sale of “Complikated” in October, the production company has sold network’s production division two new series – “You’re Not Doing It Right” and “Between Two Kings” – a rep for Red Hour told TheWrap on Monday.






Comedian Michael Ian Black writes, stars and produces in the former, a half-hour single-camera comedy based on his book of the same name that explores his childhood, marriage, children and career. Set “in the wilds of Connecticut,” the show takes a hard look at what happens when you wake up, look around and don’t recognize the life you’re living as your own, Red Hour said.


“Between Two Kings” is written and executive-produced by Jeff Kahn, who has written for series like “Drawn Together” and “The Ben Stiller Show.” It follows the hardships of a divorced father raising an 11-year-old son while living in his elderly father’s home.


Both are being executive-produced by Stiller, along with Red Hour’s Debbie Liebling and Stuart Cornfeld.


Since signing an overall deal with ABC Studios at the end of 2011, Red Hour also has sold “Please Knock,” written by Kevin Napier, and “The Notorious Mollie Flowers,” written by Adam Resnick.


The sale of “You’re Not Doing It Right” and “Between Two Kings” were first reported by Deadline.


TV News Headlines – Yahoo! News





Title Post: Ben Stiller’s Red Hour sells two more comedies to ABC Studios
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Merck, GE to collaborate on Alzheimer’s drug development






(Reuters) – Merck & Co and General Electric Co‘s healthcare unit have agreed to collaborate on an experimental drug for Alzheimer’s disease, the companies said on Tuesday.


GE Healthcare will supply Flutemetamol, an investigational imaging agent, to Merck for use with its experimental Alzheimer’s disease drug MK-8931.






The companies hope GE’s imaging agent will help identify patients who might benefit from a therapy such as Merck’s, which targets beta amyloid, a protein that can clump together and form plaques in the brain. Such plaques have been found in the brains of patients with Alzheimer’s disease.


MK-8931 is Merck’s lead Alzheimer’s drug candidate and is designed to modify progression of the disease as well as improve symptoms. Alzheimer’s robs patients of their memory and can cause other cognitive disturbances.


Based on promising results from an early-stage clinical trial of MK-8931, Merck plans to move forward with a larger trial, called EPOCH, at multiple sites around the world.


Flutemetamol is a positron emission tomography (PET) imaging agent that has been able, in clinical trials, to detect beta amyloid in the brain.


GE Healthcare will supply Flutemetamol to help select patients for clinical trials and evaluate the agent as a companion diagnostic tool. Financial and other terms of the agreement between the companies were not disclosed.


(Reporting By Toni Clarke; editing by John Wallace)


Diseases/Conditions News Headlines – Yahoo! News





Title Post: Merck, GE to collaborate on Alzheimer’s drug development
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..